Davila et al. used γ-retrovirus to produce CD19-targeting CAR-T cells, which, when combined with chemotherapy in the treatment of 16 patients with B cell acute lymphoblastic leukemia, resulted in a CR as high as 88% [422]. This evidence concerns the gene CD19 and B-cell acute lymphoblastic leukemia.